Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy
| Autor: | Seock-Ah Im, Yasuhiro Yanagita, Shintaro Takao, Isao Yokota, Soo Jung Lee, K. H. Park, Ae-Ree Kim, Sung-Bae Kim, Shoichiro Ohtani, Hironobu Sasano, Eun Sook Lee, Norikazu Masuda, Katsumasa Kuroi, Shinji Ohno, Hiroji Iwata, Masakazu Toi, Joon Jeong, Young-Hyuck Im, Byeong Woo Park, Yasuo Ohashi, Kenjiro Aogi |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Oncology medicine.medical_specialty Taxane Anthracycline business.industry medicine.medical_treatment Hazard ratio General Medicine medicine.disease Interim analysis Capecitabine 03 medical and health sciences 030104 developmental biology 0302 clinical medicine Breast cancer 030220 oncology & carcinogenesis Internal medicine Medicine business Neoadjuvant therapy Survival analysis medicine.drug |
| Zdroj: | New England Journal of Medicine. 376:2147-2159 |
| ISSN: | 1533-4406 0028-4793 |
| Popis: | BackgroundPatients who have residual invasive carcinoma after the receipt of neoadjuvant chemotherapy for human epidermal growth factor receptor 2 (HER2)–negative breast cancer have poor prognoses. The benefit of adjuvant chemotherapy in these patients remains unclear. MethodsWe randomly assigned 910 patients with HER2-negative residual invasive breast cancer after neoadjuvant chemotherapy (containing anthracycline, taxane, or both) to receive standard postsurgical treatment either with capecitabine or without (control). The primary end point was disease-free survival. Secondary end points included overall survival. ResultsThe result of the prespecified interim analysis met the primary end point, so this trial was terminated early. The final analysis showed that disease-free survival was longer in the capecitabine group than in the control group (74.1% vs. 67.6% of the patients were alive and free from recurrence or second cancer at 5 years; hazard ratio for recurrence, second cancer, or death, 0.70; 95% ... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|